Aquestive therapeutics reaffirms near-term nda resubmission for libervant™ (diazepam) buccal film following fda feedback

Warren, n.j., feb. 25, 2021 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, today announced that the food and drug administration (fda) has provided further guidance to aquestive regarding the information to be included in the new drug application (nda) for libervant™ (diazepam) buccal film for the management of seizure clusters. the further guidance from the fda addresses the revised weight-based dosing regimen, modeling and simulations data that aquestive provided to the agency in december 2020.
AQST Ratings Summary
AQST Quant Ranking